Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Avenue Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ATXI alerts

About Alexandra MacLean, M.D.

Alexandra MacLean, M.D. is recorded as Board Member at Avenue Therapeutics, Inc. (ATXI) since June 24, 2024 and CEO at Avenue Therapeutics, Inc. (ATXI) since August 1, 2022. Avenue Therapeutics, Inc. reported in an 8-K filed June 26, 2024 that Alexandra MacLean, M.D. was appointed Director, effective June 24, 2024. Avenue Therapeutics, Inc. reported in an 8-K filed March 8, 2023 that Alexandra MacLean, M.D. was appointed director, effective March 7, 2023. Avenue Therapeutics, Inc. reported in an 8-K filed August 3, 2022 that Alexandra MacLean, M.D. was appointed Chief Executive Officer, effective August 1, 2022. Avenue Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Avenue Therapeutics, Inc. includes Alexandra MacLean (CEO and Board Member), Jay Kranzler, M.D., Ph.D. (Chairman and Board Member), David Jin (CFO) and 7 others.

“the election of six directors to hold office until the 2025 annual meeting of stockholders”
Avenue Therapeutics, Inc. Form 8-K, filed June 26, 2024 · Read the filing
“On March 7, 2023, the Board of Directors (the "Board") of Avenue Therapeutics, Inc. (the "Company") voted to expand the size of the Board from five to six members, effective immediately, and appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately, with a term expiring at the 2023 Annual Meeting of Stockholders of the Company (the "Annual Meeting") or until her successor is elected and qualified, or, if earlier, her death, disability, resignation, disqualification or removal from the Board.”
Avenue Therapeutics, Inc. Form 8-K, filed March 8, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Avenue Therapeutics, Inc.

Recent activity